Stock ABIVAX (FR0012333284)
Sector : Pharmaceuticals & Biotechnology – Indices : SBF 120, CAC ALL-TRADABLE
Last update : 24/04/2026 at 17:38:53 – Source: Euronext
Market summary
As of 24/04/2026, stock ABIVAX trades at 96,00 € , with a change of -1,99 % , and a market cap of 7 612 M€. Reference period : troisième trimestre 2025 (période de neuf mois clôturée le 30 se.
Price and moving averages
Technical analysis ABIVAX
| 50-day moving average102,08 €-5.96 % (below) | Pivot96,03 € |
|---|---|
| Support level88,8 €-7.50 % | Resistance level109,6 €+14.17 % |
| 1-month volatility56,21 % | Annualised volatility194,73 % |
| RSI (14d)42 Neutral | Stochastic signal (14d)Neutre |
| ATR (14d)4,52 High volatility | CMF (21d)-0,05 Weak selling pressure |
| Bollinger bands (20d) Neutral | OBV (21d) Neutral (OBV stable) |
Recent news — ABIVAX
Abivax announces nine scientific abstracts concerning obebazimod at the Digestive Disease Week, scheduled from May 2 to May 5, 2026, in Chicago. These…
Abivax announces the presentation of nine scientific abstracts focused on obefazimod at the Digestive Disease Week conference, scheduled from May 2 to…
The stock of French biotech company Abivax significantly dropped this Monday, April 13, falling to 102.40 euros after closing at 107.90 euros on Frida…
Abivax climbs 3.41% this Friday to €109.10, driven by a spectacular increase in the price target set by Oddo BHF the previous day. The French biotech …
The French biotech company's stock increased by 2.77% this Thursday to €103.80, in a declining Paris market. This rise occurs as the CAC 40 drops by 0…
On Wednesday, April 8, the stock of the French biotech company Abivax significantly advanced in a buoyant Parisian market. Abivax traded around €103.1…
Latest earnings
| Annuels 2025 | |
|---|---|
| Revenue |
12 M€
-0,8 % |
| EBITDA | -245 M€ |
| Net income |
-336 M€
-90,7 % |
| EPS (diluted) | -4,83 € |
| Net debt | -498 M€ |
Guidance
| Management commentary | La Société s’attend à être en capacité de financer ses besoins de trésorerie prévus jusqu'au quatrième trimestre 2027. |
|---|
Identified risks and opportunities
Opportunities
- Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
- Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
- Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
Risks
- Risques inhérents à la recherche et au développement clinique
- Risque lié aux décisions des autorités réglementaires (FDA, EMA)
- Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
- Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Analyses on ABIVAX stock
No analysis has been published on this stock yet.
Frequently asked questions about ABIVAX stock
What does the recent price action of ABIVAX stock show?
ABIVAX stock is currently trading around 96,00 €, down 1,99% and down 0,07% over one week.
Is ABIVAX stock in a support or resistance zone?
Technical levels help place the stock. Support: 88,80 €. Resistance: 109,60 €.
How should the current volatility of ABIVAX stock be interpreted?
Volatility is around 194,73%.
